New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020

RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in the symptomatic PAD population,” said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Research & Development, LLC. “We have presented a total of 12 VOYAGER PAD datasets this year and continue to evaluate subgroups of PAD patients within the pivotal trials for rivaroxaban. We look forward to sharing these new analyses with the medical community at AHA.”CLICK TO TWEET: Click to learn more about PAD, including risk factors and causes; signs and symptoms; screening and prevention; health disparities and more at the @JanssenUS Cardiovascular & Metabolism online newsroom. https://ctt.ec/xe305+On October 26, 2020, Janssen announced that it submitted a supplemental New Drug Application (sNDA) to the FDA to expand the use of XARELTO® in patients with PAD to include reducing the risk of major thrombotic va...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news